May.15.2012……Ono Enters into Drug Discovery Collaboraition with Scil Proteins for Affilin® Therapeutics

May.14.2012……Results of Phase�UStudy of ONO-2745/CNS 7056, a Short-acting　General Anesthetic

May.9.2012……Announcement on Financial Results for FY2011

Apr.23.2012……Revisions of Consoldated Financial Forecasts

Apr.17.2012……ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients

Dec.22.2011……Leukotriene Receptor Antagonist "Onon® Dry Syrup 10%" has received approval for the additional indication of allergic rhinitis

Dec.13.2011……Ono Enters into Drug Discovery Collaboration with Receptos on GPCR Protein Crystal Structure Determination Technology

Dec.08.2011……Launch of an Intravenous Antiemetic Selective Neurokinin-1（NK1）Receptor Antagonist，"PROEMEND® Intravenous infusion 150mg"

Nov.30.2011……FDA Acceptance of New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.S.

Nov.14.2011……Announcement of the results from a Phase 2 study of “ONO-5163/KAI-4169”：a calcium sensing receptor agonist

Oct.20.2011……Revisions of Consolidated Financial Forecasts

Oct.04.2011……Ono to Enter into License Agreements with Merck KGaA

Sep.29.2011……Additional Indication Application Filed for a Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting“EMEND® Capsule”for Pediatric Patients Aged 12 and older

Sep.29.2011……New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.Ｓ.

Sep.26.2011……Approval received for an Intravenous Antiemetic Selective Neurokinin-1（NK₁）Receptor Antagonist，“PROEMEND® Intravenous infusion 150mg”

Sep.21.2011……Ono and Bristol-Myers Squibb Enter into Strategic Agreement for Anti-PD-1 Antibody，ONO-4538／BMS-936558，and ORENCIA®（abatacept），Rheumatoid Arthritis Agent

Sep.16.2011……Glactiv® has received approval for the additional indication of combination use with insulin

Sep.15.2011……Ono Enters License Agreement with KAI Phamaceuticals，Inc．for KAI 4169

Sep.15.2011……Launch of RECARBON® Tablets 50mg/Bonoteo® Tablet 50mg，Once per 4week Oral Osteoposis Treatment in Japan

Sep.14.2011……Ono Enters into License Agreement with Servier for Ivabradine

Sep.14.2011……Launch of Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan

Aug.24.2011……Helsinn Announced to have Initiated Global Pivotal Phase III Clinical Program to Evaluate Anamorelin (ONO-7643/RC-1291) in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia

Jul.19.2011……Launch of Rivastach® Patch，for the Treatment of Dementia of Alzheimer's Type

Jul.01.2011……Approval for RECARBON® Tablets 50mg/Bonoteo® Tablet 50mg, Once per 4weeks Oral Osteoposis treatment in Japan

Jul.01.2011……Approval for Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan

Jun.29.2011……Notice of Resolutions Passed at the 63rd Ordinary General Shareholders' Meeting

Jun.27.2011……Lead Compounds Were Successfully Identified in Ion Channel Drug Discovery Collaboration with Evotec

Jun.08.2011……Notice of the 63rd Ordinary General Shareholders' Meeting

Jun.01.2011……Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue

May.23.2011……Approval for Additional Indication Application of Type-2 Diabetes Drug,Glactiv Tablets
-Combination Therapy with Alpha-glucosidase Inhibitors-

May.11.2011……Announcement on Financial Results for FY2010

May.11.2011……Announcement on Introduct of Corporate Officer System，Changes of Members of the Board of Directors and Appointment of Corporate Officers

Apr.22,2011……Approval Received for Rivastach® Patch, for the treatment of Alzheimer's disease

Apr.06,2011……Announcement on Cancellation of the Company's Own Shares

Apr.05,2011……Launch of Orally Disintegrating Tablet of Staybla Tablets 0.1mg, a Drug for Overactive Bladder

Mar.29,2011……Ono Enters into License Agreement with OncoTherapy for New Therapeutic Cancer Peptide Vaccines

Mar.25,2011……Announcement on Results and Completion of Acquisition of the Company’s Own Shares

Jan.11,2011……Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease

Dec.10,2010……Results of Phase Ⅱb Study of Carfizomib were Presented at the 52nd American Society of Hematology Annual Meeting

Nov.11,2010……Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder

Nov.04,2010……Announcement on Acquisition of the Company's Own Shares

Oct.28,2010……Ono and MSD Submit Additional Indication Application for Sitagliptin Combination Therapy with Insulin